Drugscreen.com, announced today the introduction of its advanced screening process for the detection of K2 (synthetic marijuana) through a highly efficient test. Drugscreen.com, a division of SECON, has demonstrated that the new process can identify many of the new synthetic cannabinoid compounds being sold on the street today, making it highly successful in detecting the presence of the drug as compared to previous drug screening protocols.
Royal Philips (NYSE: PHG, AEX: PHIA) recently announced its collaboration with the University of California, Irvine, to explore how spectral breast imaging can improve breast density measurement, potentially aiding clinicians in more accurately gauging breast cancer risks and monitoring changes over time. The study will rely on Philips’ MicroDose SI mammography spectral imaging technology. Designed to address the industry’s growing concern about the lower diagnostic accuracy of mammography for high density breasts, MicroDose SI joins Philips’ suite of diagnostic imaging solutions designed to enhance imaging quality for confident diagnostics at a low dose.
Private Australian biotechnology company Minomic International Ltd will launch two overseas trials of its MiStat™ prostate cancer screening test, following an agreement with the prestigious CUSP Group, LLC a Uro-Oncology Trials Management Organisation in the United States.
Quest Diagnostics Expands Hereditary Cancer Screening Offering with Lynch Syndrome Blood and Biopsy Testing for Colorectal Cancer
Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, recently announced new pathology and blood test offerings to help identify and assess an individual’s risk of Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), an inherited genetic disorder that significantly increases the risk of colorectal and other cancers.
Florida Hospital Collaborates with VTT of Finland to Explore Research for Early Detection of Alzheimer’s Disease
Scientists from VTT and the University of Eastern Finland recently teamed up to discover a serum biochemical signature which predicts progression to Alzheimer’s disease. From this, VTT was able to develop a biomarker assay. Florida Hospital and VTT have since come together to evaluate screening, diagnostic and prognostic potential of the biomarker essay.